Drug Overview

The PI3Kbeta inhibitor AZD8186 is an experimental medication designed to treat advanced cancers. It is a specialized form of Targeted Therapy often called a “Smart Drug.” Unlike standard chemotherapy that attacks all fast-growing cells, this drug is engineered to find and block specific “switches” inside cancer cells that allow them to grow and hide from the body’s natural defenses.

By focusing on a specific version of a protein (the beta version), AZD8186 aims to stop the cancer’s progression while causing less harm to healthy parts of the body. It is currently being used in global clinical trials for patients with difficult-to-treat solid tumors.

Generic Name: AZD8186
US Brand Names: None (Currently an investigational agent)
Drug Class: Phosphoinositide 3-kinase (PI3K) beta-selective inhibitor; Targeted Therapy
Route of Administration: Oral (Tablet)
FDA Approval Status: Not FDA Approved (Available only through clinical trials)

What Is It and How Does It Work? (Mechanism of Action)

To understand how AZD8186 works, imagine a cancer cell has an internal “command center.” One of the most important control switches in this center is called PI3K (Phosphoinositide 3-kinase).

At the molecular level, AZD8186 works through a very specific process:

Targeting the Beta (beta) Switch: The PI3K enzyme comes in different forms called isoforms. AZD8186 is a “selective” inhibitor, meaning it specifically targets the beta isoform. This switch is often stuck in the “ON” position in tumors that have lost a protective “brake” protein called PTEN.
Interrupting the Signaling Chain: Once the drug enters the cancer cell, it binds to the PI3K-beta protein. This stops the production of a signaling molecule called PIP3.
Shutting Down Growth: Without PIP3, a secondary protein called Akt cannot be activated. This breaks the PI3K/Akt/mTOR signaling pathway. This pathway is the primary “instruction manual” the cell uses to grow, multiply, and ignore signals to die.
Starving the Cancer: By silencing this pathway, the cancer cell can no longer repair itself or divide. Eventually, the cell undergoes apoptosis (programmed cell death), where it essentially recognizes it is broken and destroys itself.

FDA-Approved Clinical Indications

As of early 2026, AZD8186 has not received full FDA approval. It is strictly available through clinical research studies for specific patient populations.

Oncological Uses (Investigational):

PTEN-Deficient Solid Tumors: Including specific types of prostate, breast, and lung cancers.
Triple-Negative Breast Cancer (TNBC): Often studied in combination with other treatments.
Metastatic Castration-Resistant Prostate Cancer (mCRPC): For patients whose cancer has stopped responding to hormone therapy.

Non-oncological Uses:

None.

Dosage and Administration Protocols

Because AZD8186 is in the clinical trial phase, the dosage is determined by the specific research study a patient joins. It is typically taken by mouth.

Protocol Detail	Standard Trial Information
Standard Dose	Ranges from 30 mg to 120 mg (depending on trial phase)
Frequency	Usually twice daily (BID)
Timing	Should be taken at the same time each day
Schedule	Often given on a “4 days on, 3 days off” or continuous schedule

Dose Adjustments: If a patient develops signs of liver stress or severe skin rashes, the trial doctor may lower the dose or pause treatment. Specific adjustments for renal (kidney) or hepatic (liver) insufficiency are currently under investigation in Phase 1/2 studies.

Clinical Efficacy and Research Results

Clinical data from 2020–2025 has focused on how well AZD8186 can control tumors that have become resistant to other drugs.

Disease Control: In early-phase trials, AZD8186 has shown the ability to achieve “Stable Disease” in approximately 35% to 45% of patients with advanced solid tumors.
PTEN Sensitivity: Research confirms that patients whose tumors have a PTEN mutation respond more effectively to the beta-inhibitor characteristics of this drug.
Numerical Data: Early reports from combination studies (pairing AZD8186 with hormone therapy or other inhibitors) suggest a “Clinical Benefit Rate” of roughly 40% in specific groups of patients with prostate and breast cancers.

Safety Profile and Side Effects

Like other Targeted Therapies in its class, AZD8186 has a specific set of side effects because the PI3K pathway is also used by some healthy cells.

Black Box Warning

None. (Investigational drugs do not receive Black Box Warnings until they are fully FDA-approved).

Common Side Effects (>10%)

Diarrhea: The most common side effect, often manageable with standard medicine.
Nausea: Mild to moderate upset stomach.
Fatigue: A general feeling of tiredness or low energy.
Skin Rash: Redness or itching that usually responds to creams.

Serious Adverse Events

Hepatotoxicity: Signs of liver stress, shown by high enzymes in blood tests.
Hyperglycemia: High blood sugar (since PI3K helps insulin work).
Colitis: Severe inflammation of the colon causing pain and diarrhea.

Management Strategies

Glucose Tracking: Patients may need to check their blood sugar levels regularly.
Liver Monitoring: Frequent blood work is required to ensure the liver is processing the drug safely.

Research Areas

In the fields of Immunotherapy and regenerative medicine, AZD8186 is a drug of great interest. Researchers are currently studying if blocking the PI3K-beta pathway can “reprogram” the environment around a tumor. By shutting down the signals that help cancer hide, the drug may help the body’s regenerating immune cells (like T-cells) see the cancer more clearly. Ongoing trials are exploring AZD8186 in combination with Immune Checkpoint Inhibitors to see if this “one-two punch” creates a more durable defense against cancer.

Patient Management and Practical Recommendations

Pre-treatment Tests to be Performed

Genetic Testing: To confirm if the tumor has a PTEN mutation or PI3K genetic changes.
Liver Function Panel: To establish a baseline for liver health.
Fasting Glucose: To check your baseline blood sugar level.

Precautions During Treatment

Monitor Bowel Habits: Report any sudden increase in diarrhea to your oncology team immediately.
Sun Protection: Some patients may become more sensitive to sunlight; use SPF and hats.

“Do’s and Don’ts” List

DO report any new skin rash or itchy skin to your doctor right away.
DO take the medication at the same time every day to keep the drug levels steady.
DON’T stop the medication without talking to your trial team, even if you feel tired.
DON’T take new over-the-counter supplements without checking, as they may interfere with the drug.

Legal Disclaimer

The medical information provided in this guide is for educational and informational purposes only and does not substitute for professional medical advice, diagnosis, or treatment. AZD8186 is an experimental drug and is only available through clinical trials. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition or participation in clinical research.